ArticlePregnancy (Hoboken, N.J.)2025
Characterization of substance use disorder during pregnancy in a syphilis population.
Article in Pregnancy (Hoboken, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Rates of congenital syphilis and substance use disorder (SUD) have concurrently risen in pregnant patients. Specific substances and their association with inadequately treated syphilis have not yet been identified. The objective of our study was to characterize SUD, including specific drugs of use, among pregnant people with syphilis to determine the association between SUD and adequacy of syphilis treatment. Methods: Patients diagnosed with syphilis during pregnancy between January 1, 2021 and December 31, 2022 were identified. SUD was identified via chart review and confirmed or supported by the use of universal screening for self-reported SUD, ICD-10 codes for mothers and neonates, and toxicology. Maternal demographics and delivery and neonatal outcomes were compared among those with and without SUD. Logistic regression models adjusted for maternal age, Black race, nulliparity, and hypertension were used to produce odds ratios relating SUD to delivery and neonatal outcomes. The timing of penicillin treatment initiation less than 30 days versus 30 or more days before delivery in individuals with and without SUD was compared. Results: Of 225 patients with syphilis during pregnancy, 40 (17.8%) had SUD. Compared to those without SUD, those diagnosed with SUD were more likely to be Non-Hispanic White with late and limited prenatal care. They were almost six times more likely to have preterm delivery (aOR 5.98 [95% CI 2.47-14.79]) and three times more likely to develop pre-eclampsia with severe features (aOR 3.48 [95% CI 1.41-8.41]). The most common primary drugs of use included non-prescription opioids (32%), methamphetamines (32%), and cannabis (20%). Frequency of syphilis treatment initiation less than 30 days before delivery was higher in individuals with SUD (52% vs. 21%, Conclusions: Pregnant people with SUD, and specifically use of methamphetamines, were more likely to have inadequate syphilis treatment than those without SUD. In addition, demographic and prenatal characteristics differed between individuals with and without SUD, with poorer delivery outcomes observed in patients with SUD and syphilis compared to a syphilis population alone. Future research is needed that addresses the impact of medication-assisted therapies for the treatment of methamphetamine use on rates of adequate syphilis treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.